Researchers reported a strategy to genetically program neutrophils in vivo for glioma treatment, targeting a longstanding limitation in cell-based engineering. The work describes direct genetic modification of neutrophils—cells that are abundant in circulation and act within the tumor microenvironment—while addressing prior difficulty in programming them for therapeutic use. In a preclinical framing, the approach aims to turn neutrophils into an effective in situ delivery platform for glioma, potentially broadening the cellular immunotherapy toolbox beyond more commonly engineered lymphocytes. The announcement adds to the momentum in engineered innate-cell therapies for solid tumors, where tumor trafficking and durable activity have remained key development hurdles.